SEQUEL

About SEQUEL

Sequel provides an automated insulin delivery (AID) system that utilizes the Tidepool algorithm for precise insulin measurement and delivery, enabling personalized diabetes management. The company addresses the lack of access to effective insulin therapy for the 63% of insulin-dependent diabetes patients not currently using AID systems.

```xml <problem> Many insulin-dependent diabetes patients lack access to automated insulin delivery (AID) systems, resulting in suboptimal diabetes management and health outcomes. Existing AID systems can be expensive or require complex management, creating barriers to access for a significant portion of the population. </problem> <solution> Sequel provides an accessible and affordable AID system designed to improve diabetes management for a broader range of patients. The system leverages precise measurement technology to ensure accurate insulin delivery and is powered by the Tidepool algorithm, which automatically adjusts insulin delivery based on real-world data. By offering a simplified and personalized approach to insulin therapy, Sequel aims to remove barriers to access and improve the health and well-being of people with diabetes. The system is designed for everyday wear and is available through pharmacy channels, increasing its accessibility. </solution> <features> - Precise insulin measurement technology for accurate delivery. - Powered by the Tidepool algorithm for automated insulin adjustments. - Designed for everyday wear. - Available through pharmacy channels for simplified access. </features> <target_audience> The primary target audience includes healthcare providers and people with diabetes, as well as employers and consultants seeking to transform health plan benefits with next-generation insulin therapy access. </target_audience> ```

What does SEQUEL do?

Sequel provides an automated insulin delivery (AID) system that utilizes the Tidepool algorithm for precise insulin measurement and delivery, enabling personalized diabetes management. The company addresses the lack of access to effective insulin therapy for the 63% of insulin-dependent diabetes patients not currently using AID systems.

When was SEQUEL founded?

SEQUEL was founded in 2001.

Founded
2001
Employees
27 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

Start Searching

SEQUEL

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Sequel provides an automated insulin delivery (AID) system that utilizes the Tidepool algorithm for precise insulin measurement and delivery, enabling personalized diabetes management. The company addresses the lack of access to effective insulin therapy for the 63% of insulin-dependent diabetes patients not currently using AID systems.

sequelmedtech.com7K+
Founded 2001

Funding

No funding information available.

Team (25+)

No team information available.

Company Description

Problem

Many insulin-dependent diabetes patients lack access to automated insulin delivery (AID) systems, resulting in suboptimal diabetes management and health outcomes. Existing AID systems can be expensive or require complex management, creating barriers to access for a significant portion of the population.

Solution

Sequel provides an accessible and affordable AID system designed to improve diabetes management for a broader range of patients. The system leverages precise measurement technology to ensure accurate insulin delivery and is powered by the Tidepool algorithm, which automatically adjusts insulin delivery based on real-world data. By offering a simplified and personalized approach to insulin therapy, Sequel aims to remove barriers to access and improve the health and well-being of people with diabetes. The system is designed for everyday wear and is available through pharmacy channels, increasing its accessibility.

Features

Precise insulin measurement technology for accurate delivery.

Powered by the Tidepool algorithm for automated insulin adjustments.

Designed for everyday wear.

Available through pharmacy channels for simplified access.

Target Audience

The primary target audience includes healthcare providers and people with diabetes, as well as employers and consultants seeking to transform health plan benefits with next-generation insulin therapy access.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.